Elutia Inc. (ELUT) - Total Assets
Based on the latest financial reports, Elutia Inc. (ELUT) holds total assets worth $62.35 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ELUT equity to assets ratio to measure how much of total assets are equity-financed.
Elutia Inc. - Total Assets Trend (2018–2025)
This chart illustrates how Elutia Inc.'s total assets have evolved over time, based on quarterly financial data. Check Elutia Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
Elutia Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Elutia Inc.'s total assets of $62.35 Million consist of 89.5% current assets and 10.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 58.3% |
| Accounts Receivable | $6.58 Million | 10.6% |
| Inventory | $2.62 Million | 4.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.53 Million | 2.5% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Elutia Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ELUT market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Elutia Inc.'s current assets represent 89.5% of total assets in 2025, an increase from 38.0% in 2018.
- Cash Position: Cash and equivalents constituted 58.3% of total assets in 2025, up from 5.1% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 10.6% of total assets.
Elutia Inc. Competitors by Total Assets
Key competitors of Elutia Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Elutia Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 0.69 | 1.74 |
| Quick Ratio | 2.12 | 0.59 | 1.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $30.68 Million | $-11.62 Million | $16.74 Million |
Elutia Inc. - Advanced Valuation Insights
This section examines the relationship between Elutia Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.70 |
| Latest Market Cap to Assets Ratio | 0.70 |
| Asset Growth Rate (YoY) | 72.6% |
| Total Assets | $62.35 Million |
| Market Capitalization | $43.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values Elutia Inc.'s assets below their book value (0.70x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Elutia Inc.'s assets grew by 72.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Elutia Inc. (2018–2025)
The table below shows the annual total assets of Elutia Inc. from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $62.35 Million | +72.59% |
| 2024-12-31 | $36.13 Million | -16.81% |
| 2023-12-31 | $43.43 Million | -36.92% |
| 2022-12-31 | $68.84 Million | +2.49% |
| 2021-12-31 | $67.17 Million | -18.89% |
| 2020-12-31 | $82.81 Million | +84.96% |
| 2019-12-31 | $44.77 Million | -6.22% |
| 2018-12-31 | $47.74 Million | -- |
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDer… Read more